Eleni Aklillu
Eleni Aklillu
Associate Professor of Pharmacology, Karolinska Institutet
Verifierad e-postadress på ki.se
TitelCiteras avÅr
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants
SC Sim, C Risinger, ML Dahl, E Aklillu, M Christensen, L Bertilsson, ...
Clinical Pharmacology & Therapeutics 79 (1), 103-113, 2006
7372006
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles.
E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, ...
Journal of pharmacology and experimental therapeutics 278 (1), 441-446, 1996
4621996
Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population
MG Scordo, E Aklillu, U Yasar, ML Dahl, E Spina, M Ingelman‐Sundberg
British journal of clinical pharmacology 52 (4), 447-450, 2001
2602001
Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans
R Ghotbi, M Christensen, HK Roh, M Ingelman-Sundberg, E Aklillu, ...
European journal of clinical pharmacology 63 (6), 537-546, 2007
2172007
Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1
E Aklillu, JA Carrillo, E Makonnen, K Hellman, M Pitarque, L Bertilsson, ...
Molecular pharmacology 64 (3), 659-669, 2003
2082003
Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population
E Aklillu, M Oscarson, M Hidestrand, B Leidvik, C Otter, ...
Molecular pharmacology 61 (3), 586-594, 2002
1742002
4β-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
U Diczfalusy, J Miura, HK Roh, RA Mirghani, J Sayi, H Larsson, KG Bodin, ...
Pharmacogenetics and genomics 18 (3), 201-208, 2008
1382008
A novel polymorphism in ABCB1 gene, CYP2B6* 6 and sex predict single‐dose efavirenz population pharmacokinetics in Ugandans
JK Mukonzo, D Röshammar, P Waako, M Andersson, T Fukasawa, ...
British journal of clinical pharmacology 68 (5), 690-699, 2009
1122009
Long‐term efavirenz autoinduction and its effect on plasma exposure in HIV patients
E Ngaimisi, S Mugusi, OM Minzi, P Sasi, KD Riedel, A Suda, N Ueda, ...
Clinical Pharmacology & Therapeutics 88 (5), 676-684, 2010
1052010
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype
Z Jiang, N Dragin, LF Jorge-Nebert, MV Martin, FP Guengerich, E Aklillu, ...
Pharmacogenetics and genomics 16 (5), 359-367, 2006
1032006
S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians
I Persson, E Aklillu, F Rodrigues, L Bertilsson, M Ingelman-Sundberg
Pharmacogenetics 6 (6), 521-526, 1996
961996
Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa …
E Ngaimisi, A Habtewold, O Minzi, E Makonnen, S Mugusi, W Amogne, ...
PloS one 8 (7), e67946, 2013
922013
Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients
G Yimer, N Ueda, A Habtewold, W Amogne, A Suda, KD Riedel, ...
PLoS One 6 (12), e27810, 2011
902011
Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes
N Djordjevic, R Ghotbi, L Bertilsson, S Jankovic, E Aklillu
European journal of clinical pharmacology 64 (4), 381-385, 2008
872008
Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2− 163C> A polymorphism
N Djordjevic, R Ghotbi, S Jankovic, E Aklillu
European journal of clinical pharmacology 66 (7), 697-703, 2010
852010
High plasma efavirenz level and CYP2B6*6 are associated with efavirenz-based HAART-induced liver injury in the treatment of naïve HIV patients from Ethiopia: a …
G Yimer, W Amogne, A Habtewold, E Makonnen, N Ueda, A Suda, ...
The pharmacogenomics journal 12 (6), 499, 2012
812012
Towards host-directed therapies for tuberculosis
A Zumla, J Chakaya, M Hoelscher, F Ntoumi, R Rustomjee, C Vilaplana, ...
Nature reviews Drug discovery 14 (8), 511, 2015
802015
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
RA Mirghani, J Sayi, E Aklillu, A Allqvist, M Jande, A Wennerholm, ...
Pharmacogenetics and genomics 16 (9), 637-645, 2006
802006
Keratin‐18 and micro RNA‐122 complement alanine aminotransferase as novel safety biomarkers for drug‐induced liver injury in two human cohorts
P Thulin, G Nordahl, M Gry, G Yimer, E Aklillu, E Makonnen, G Aderaye, ...
Liver international 34 (3), 367-378, 2014
772014
Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden
E Aklillu, K Herrlin, LL Gustafsson, L Bertilsson, M Ingelman-Sundberg
Pharmacogenetics and Genomics 12 (5), 375-383, 2002
772002
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20